Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Total Current Assets history
Currency unavailable · from the balance sheet
No Total Current Assets data reported for this period type.
Total Current Assets vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $484.7M USD | +66.6% | +151.7% | 97.4% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $389.07M USD | +2532.3% | +143.0% | 98.9% |
| Mar 2026 | $327.23M USD | +233.0% | +116.4% | 78.1% | |
| Mar 2026 | $293.17M USD | -28.1% | -12.6% | 67.6% | |
| Mar 2026 | $272.23M USD | -7.6% | +19.3% | 98.9% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $252.96M USD | +31.7% | +76.9% | 96.8% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.43M USD | -39.8% | -21.1% | 99.7% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +31.7% | +76.9% | 97.4% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.